Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives $29.67 Average Price Target from Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has earned a consensus recommendation of “Hold” from the five analysts that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $29.6667.

ETON has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research upgraded Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Finally, Wall Street Zen lowered shares of Eton Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, December 13th.

Eton Pharmaceuticals Stock Performance

Shares of Eton Pharmaceuticals stock opened at $17.07 on Wednesday. The stock has a market cap of $457.82 million, a price-to-earnings ratio of -68.28 and a beta of 1.19. Eton Pharmaceuticals has a twelve month low of $11.09 and a twelve month high of $23.00. The company’s fifty day moving average is $15.90 and its 200 day moving average is $17.05. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Divisadero Street Capital Management LP bought a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth about $7,092,000. Geode Capital Management LLC grew its stake in Eton Pharmaceuticals by 98.8% during the second quarter. Geode Capital Management LLC now owns 592,865 shares of the company’s stock worth $8,450,000 after purchasing an additional 294,617 shares during the period. Soleus Capital Management L.P. bought a new stake in Eton Pharmaceuticals in the second quarter worth approximately $4,061,000. Millennium Management LLC lifted its stake in Eton Pharmaceuticals by 156.3% in the first quarter. Millennium Management LLC now owns 355,929 shares of the company’s stock valued at $4,620,000 after buying an additional 217,042 shares during the period. Finally, Oberweis Asset Management Inc. acquired a new position in Eton Pharmaceuticals in the third quarter valued at approximately $4,180,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.